Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2004

View Archived Issues

New polymeric cytotoxic agents developed by Sankyo scientists

Novel antitumor protein kinase inhibitors under study at Abbott

Novel SGLT inhibitors prepared and tested by Yamanouchi and Kotobuki scientists

Novartis claims aldosterone synthase inhibitors and their use

Novel antifungal agents isolated and tested at Meiji Seika

Novel tachykinin NK1 antagonists covered by Tanabe Seiyaku patent

Exercise and metformin improve cardiovascular parameters in HIV-infected patients

Safety and pharmacokinetics of a human monoclonal antibody for anthrax

Improved diagnosis of stenosis achieved with the contrast agent MS-325

Diagnostic benefits of the contrast agent SHL-643A in magnetic resonance imaging

Novel selective TGF-beta inhibitor by GlaxoSmithKline

PARP inhibitor HO-3089 demonstrates both cardioprotective and antithrombotic potential

Phase IIa results for diabetic complication drug AS-3201

Cangene to evaluate WinRho SDF for dengue hemorrhagic fever

Enrollment completed in phase II study of SPI-0211 for IBS

NM-100061 produces positive results in early ejaculation study

Astex Technology joins BRAF drug discovery collaboration

Aplidin enters phase I for pediatric solid tumors and hematological malignancies

Siga completes successful smallpox vaccine study

Pharmacopeia extends and expands research collaboration with Celgene

OraQuick Rapid HIV-1/2 Antibody Test receives FDA approval

Protein Mechanics and Aventis enter MMP inhibitor research collaboration

SBIR grant supports development of novel anti-HIV therapeutics at Aphios

European filing for Antegren for MS planned for summer

Proteome Sciences licenses biomarkers for Alzheimer's disease

HuMax-CD4 receives fast track designation for cutaneous T-cell lymphoma

Pharmexa shifts strategic focus from research to development

Ligand reports progress during 2003

Antidepressant and anxiolytic potential of MGS-0039, a potent, selective group II mGluR antagonist

Chronic administration of (-)-BPAP may be effective against stress disorders

Potent neuroprotective effects of FR-210575, a powerful free radical scavenger